Recent Updates
Recently added Catalysts

tasimelteon

Phase 3

Non-24-Hour Sleep-Wake Disorder | Small molecule | Other |Vanda Pharmaceuticals Inc.|Last Updated: Apr 21, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials3
Total Enrollment356
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01429116Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionPHASE3 COMPLETED 200Oct 1, 2011Jan 1, 2015Apr 21, 201522 United States
NCT01430754Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake DisorderPHASE3 COMPLETED 20Sep 1, 2011Dec 1, 2012Oct 10, 201422 United States
NCT01163032Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderPHASE3 COMPLETED 136Aug 1, 2010Nov 1, 2012Oct 16, 201428 United States, Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with Treatment-Emergent Adverse Events (AEs)
24 months + 12 month optional extension

Treatment-emergent adverse events will be summarized by presenting the number and percentage of patients having any treatment-emergent AE, having an AE in each body system, and having each individual AE.

Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.
Approximately 12 weeks

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI \>24.0.

Proportion of Patients Entrained as Assessed by Urinary aMT6
1 month

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.

Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS
6 months

Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.

Secondary Endpoints
Number of participants with changes in Clinical Laboratory Data
24 months + 12 month optional extension
Number of participants with newly occurring or worsening ECG abnormalities
24 months + 12 month optional extension
Number of participants with clinically notable Vital Signs and Body Measurements
24 months + 12 month optional extension
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
tasimelteonEXPERIMENTAL20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
PlaceboPLACEBO_COMPARATORPlacebo capsules
Interventions
NameTypeDescription
tasimelteonDRUG20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
PlaceboDRUGPlacebo capsules, daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria: 1. Ability and acceptance to provide informed consent; 2. Men or women at least 18 years of age or older who meet one of the following: * Has enrolled in VP-VEC-162-3201 (with sponsor approval) * Has completed VP-VEC-162-3203 * Was deemed a non-responder in VP-VEC-162-...

Countries:United StatesGermany
Unlock Eligibility Criteria